Blueprint Medicines Overview
Blueprint Medicines (BPMC) has a ROE of -45.52%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-45.52%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Blueprint Medicines (BPMC) currently reports a ROE of -45.52%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Blueprint Medicines's ROE history and peer comparisons.
Blueprint Medicines's ROE of -45.52% is higher than the Healthcare sector average of -100.59%. That is roughly 54.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Blueprint Medicines's current -45.52% should be judged against Healthcare norms (sector average: -100.59%) and against BPMC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -45.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.
Blueprint Medicines is classified in the Healthcare sector. On ROE, it currently shows -45.52% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BPMC with unrelated industries.
